Segment information

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Segment information

9. Segment information

The CODM has been identified as the CEO. The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it has a single operating segment composed of the consolidated financial results of Bone Biologics Corporation.

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

	Year ended December 31,
	2025			2024
Revenue	$	-		$	-
Less:
Research and development		1,060,191			2,130,385
Salaries		650,000			581,163
Insurance		285,339			391,697
Stock-based compensation		256,358			188,819
Operating expenses		983,054			927,097
Other income		(125,951	)		(106,741	)
Net loss	$	(3,108,991	)	$	(4,112,420	)